Not all patients with CLL call for therapy. Despite all recent innovations, the iwCLL continue to suggests watchful observation for clients with asymptomatic disease.86 This advice is predicated on no less than two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,10